Trenton, NJ – Adults in New Jersey who are prescribed certain medications to treat attention deficit hyperactivity disorder (ADHD) will soon have greater flexibility in maintaining their prescriptions under a new law signed by Gov. Mikie Sherrill.
The legislation allows adults prescribed Schedule II stimulant medications—including Adderall, Ritalin, and Vyvanse—to complete required follow-up appointments through telehealth rather than attending in-person doctor’s visits every three months.
New telehealth option for prescription renewals
Under the new law, patients who have already completed an initial in-person evaluation may continue receiving prescription renewals through telehealth appointments.
If a patient’s initial evaluation is conducted remotely, the law requires an in-person examination within 30 days. After that, patients must be seen in person at least once each year while continuing treatment.
The change is intended to reduce barriers to care while maintaining safeguards for patients taking controlled substances.
Law affects Schedule II ADHD medications
The law applies to adults prescribed Schedule II stimulant medications commonly used to treat ADHD, including Adderall, Ritalin, and Vyvanse.
These medications are classified as controlled substances under federal law because they have a recognized medical use but also carry the potential for abuse and dependence.
Supporters of the legislation say allowing routine follow-up appointments by telehealth can improve access to treatment, particularly for patients who have difficulty scheduling frequent office visits.
Related: New Jersey, Mikie Sherrill, ADHD, Telehealth, Adderall
